Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytosorbents Cor (NQ: CTSO )

0.9101 -0.0299 (-3.18%)
Streaming Delayed Price Updated: 11:33 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,566
Open 0.9050
Bid (Size) 0.9100 (20)
Ask (Size) 0.9388 (1)
Prev. Close 0.9400
Today's Range 0.9050 - 0.9300
52wk Range 0.7820 - 4.290
Shares Outstanding 54,306,415
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CTSO Stock Earnings: CytoSorbents Meets EPS, Beats Revenue for Q1 2024
CTSO stock results show that CytoSorbents met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
CytoSorbents Reports First Quarter 2024 Results
From CytoSorbents
Via GlobeNewswire

Performance

YTD
-14.94%
-14.94%
1 Month
+12.36%
+12.36%
3 Month
-8.99%
-8.99%
6 Month
-26.60%
-26.60%
1 Year
-74.51%
-74.51%

More News

Read More
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
From CytoSorbents
Via GlobeNewswire
Recap: CytoSorbents Q4 Earnings
Via Benzinga
A Preview Of CytoSorbents's Earnings
Via Benzinga
What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents
Via Benzinga
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
From CytoSorbents
Via GlobeNewswire
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
From CytoSorbents
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Via Benzinga
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
From CytoSorbents
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
From CytoSorbents
Via GlobeNewswire
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Gold Moves Lower; US Crude Stocks Decline Last Week
Via Benzinga
Topics Stocks
Exposures US Equities
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Down 1%; US Wholesale Inventories Fall In November
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Gains 50 Points; US Jobless Claims Rise To 218,000
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
From CytoSorbents
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.